Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
PARSIPPANY, N.J., April 27, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 4, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 4977296. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 4977296. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
